NCT05521984View on ClinicalTrials.gov

Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 3, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

November 30, 2026

Conditions
Pediatric Brain TumorPediatric Solid Tumor
Interventions
DRUG

Dapagliflozin

Commercially available

DRUG

Carmustine

Standard of care

DRUG

Topotecan

Standard of care

DRUG

Cyclophosphamide

Standard of care

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine/St. Louis Children's Hospital, St Louis

All Listed Sponsors
collaborator

Children's Discovery Institute

OTHER

lead

Washington University School of Medicine

OTHER